Summary.
BDM (2,3-butanedione monoxime) has been used extensively to inhibit nonmuscle myosin. However, recent articles raise the question of what BDM actually does, because of experiments in which BDM did not affect the actin-activated ATPase of nonmuscle myosins. We describe results that indicate that BDM indeed inhibits motility due to nonmuscle myosins: in many different cells BDM has the same effects as anti-actin agents and/or as other anti-myosin agents, and BDM slows or stops the sliding between actin filaments and myosin in vitro. We discuss how the two sets of apparently contradictory results might be resolved, and we suggest possible experiments that might clarify the contradictory interpretations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Correspondence and reprints: Biology Department, York University, 4700 Keele Street, Toronto, ON M3J 1P3, Canada.
Rights and permissions
About this article
Cite this article
Forer, A., Fabian, L. Does 2,3-butanedione monoxime inhibit nonmuscle myosin?. Protoplasma 225, 1–4 (2005). https://doi.org/10.1007/s00709-004-0077-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00709-004-0077-z